Brendon J. Yee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Brendon J. Yee has a total of 107 co-authors. Here are the top co-authors by number of shared publications:
- Ronald R. Grunstein
Woolcock Institute of Medical Research, Macquarie University Sydney New South Wales Australia
7 shared publications - Steven Luu
Sleep and Circadian Research Group, Woolcock Institute of Medical Research, Macquarie University, Macquarie Park, Australia
6 shared publications - Amanda Jane Piper
Department of Respiratory and Sleep Medicine Royal Prince Alfred Hospital Camperdown New South Wales Australia
5 shared publications - Craig L. Phillips
CIRUS, Centre for Sleep and Chronobiology, Woolcock Institute of Medical Research, Macquarie University Sydney New South Wales Australia
4 shared publications - Peter A. Cistulli
Charles Perkins Centre, Faculty of Medicine and Health University of Sydney Sydney New South Wales Australia
4 shared publications - Andrew S. L. Chan
Sleep Research Group, Charles Perkins Centre, University of Sydney, Sydney, Australia
3 shared publications
Latest Publications
- Open Access
- 26 October 2026
- Published by Taylor & Francis in COPD: Journal of Chronic Obstructive Pulmonary Disease
- Vol. 23 (1)
Impact of Schizophrenia on Outcomes Following Non-Invasive Ventilation for Acute Hypercapnic Respiratory Failure in COPD
- 26 October 2026
- Published by Taylor & Francis in COPD: Journal of Chronic Obstructive Pulmonary Disease
- Vol. 23 (1)
Open AccessImpact of Schizophrenia on Outcomes Following Non-Invasive Ventilation for Acute Hypercapnic Respiratory Failure in COPD
- Open Access
- 7 August 2026
- Published by Wiley in Journal of Sleep Research
- p. e70421
Does Hypoxic Burden Better Explain Sex Differences in Functional Impairments Than Apnoea‐Hypopnoea Index in Obstructive Sleep Apnoea?
Women with obstructive sleep apnoea (OSA) report more severe functional impairments than men, despite lower apnoea‐hypopnoea index (AHI) values. This raises questions about the adequacy of AHI for capturing OSA severity. We explored sex differences in functional outcomes in OSA patients and examined whether AHI or hypoxic burden (HB) better explained these differences. We analysed cross‐sectional data from Sydney Sleep Biobank (2018–2023). Adults with OSA (AHI ≥ 5 events/h on polysomnography) with data on mood (Depression, Anxiety and Stress Scale; DASS‐21) and daytime functioning (Functional Outcomes of Sleep Questionnaire; FOSQ‐10) were included. Linear regression models examined associations between sex, AHI, HB and functional outcomes. Interaction effects of sex and AHI/HB were explored. Among 518 untreated OSA patients (67.7% men, mean age = 54.0, SD = 14.6 years), women had significantly higher DASS‐21 (15.4 vs. 12.1, p < 0.01) and lower FOSQ‐10 (14.1 vs. 16.0, p < 0.0001) scores, despite lower AHI (28.7 vs. 32.9, p = 0.10) and HB (47.4 vs. 82.7, p < 0.001). Neither AHI nor HB was associated with worse mood, although AHI was linked to poorer mood in women in sensitivity analyses. AHI and HB were associated with worse FOSQ‐10. In multivariable models adjusting for demographics, anthropometry, comorbidities and medications, neither AHI nor HB consistently predicted mood or daytime functioning. Sex differences in mood were explained by comorbid mood disorders, insomnia and chronic pain. Women had more severe functional impairments despite milder respiratory indices. Given the greater influence of comorbidities on functional outcomes than respiratory metrics, comprehensive comorbidity assessment in OSA evaluation is warranted, especially in females.
- 7 August 2026
- Published by Wiley in Journal of Sleep Research
- p. e70421
Open AccessDoes Hypoxic Burden Better Explain Sex Differences in Functional Impairments Than Apnoea‐Hypopnoea Index in Obstructive Sleep Apnoea?
Women with obstructive sleep apnoea (OSA) report more severe functional impairments than men, despite lower apnoea‐hypopnoea index (AHI) values. This raises questions about the adequacy of AHI for capturing OSA severity. We explored sex differences in functional outcomes in OSA patients and examined whether AHI or hypoxic burden (HB) better explained these differences. We analysed cross‐sectional data from Sydney Sleep Biobank (2018–2023). Adults with OSA (AHI ≥ 5 events/h on polysomnography) with data on mood (Depression, Anxiety and Stress Scale; DASS‐21) and daytime functioning (Functional Outcomes of Sleep Questionnaire; FOSQ‐10) were included. Linear regression models examined associations between sex, AHI, HB and functional outcomes. Interaction effects of sex and AHI/HB were explored. Among 518 untreated OSA patients (67.7% men, mean age = 54.0, SD = 14.6 years), women had significantly higher DASS‐21 (15.4 vs. 12.1, p < 0.01) and lower FOSQ‐10 (14.1 vs. 16.0, p < 0.0001) scores, despite lower AHI (28.7 vs. 32.9, p = 0.10) and HB (47.4 vs. 82.7, p < 0.001). Neither AHI nor HB was associated with worse mood, although AHI was linked to poorer mood in women in sensitivity analyses. AHI and HB were associated with worse FOSQ‐10. In multivariable models adjusting for demographics, anthropometry, comorbidities and medications, neither AHI nor HB consistently predicted mood or daytime functioning. Sex differences in mood were explained by comorbid mood disorders, insomnia and chronic pain. Women had more severe functional impairments despite milder respiratory indices. Given the greater influence of comorbidities on functional outcomes than respiratory metrics, comprehensive comorbidity assessment in OSA evaluation is warranted, especially in females.
- Open Access
- 4 August 2026
- Published by Wiley in Journal of Sleep Research
- p. e70429
Targeting Orexin 2 Receptors in Idiopathic Hypersomnia and Narcolepsy: A Randomised Phase 1b Proof‐Of‐Concept Study of Alixorexton
Idiopathic hypersomnia (IH) and narcolepsy type 2 (NT2) are central disorders of hypersomnolence characterised by excessive daytime sleepiness and substantial functional burden. Narcolepsy type 1 (NT1), defined by orexin deficiency, serves as an established biologic standard for evaluating therapies targeting the orexin system. Alixorexton (ALKS 2680) is a highly potent, oral, selective orexin 2 receptor (OX2R) agonist in clinical development for IH, NT2 and NT1. In this phase 1b, randomised, double‐blind, placebo‐controlled, four‐way crossover study (ISRCTN98204977), adults aged 18–65 years with IH ( n = 8), NT2 ( n = 9) or NT1 ( n = 10) received single oral doses of alixorexton (IH/NT2: 5, 12, 25 mg; NT1: 1, 3, 8 mg) and placebo across four treatment periods. The primary endpoint was safety and tolerability. Wakefulness was assessed by mean sleep latency on the Maintenance of Wakefulness Test (MWT) over 8 h post‐dose and subjective alertness by the Karolinska Sleepiness Scale (KSS). Alixorexton was generally well tolerated; all treatment‐emergent adverse events (TEAEs) were mild or moderate, with no serious TEAEs and no discontinuations due to TEAEs. In IH and NT2, alixorexton demonstrated statistically significant, clinically meaningful, dose‐dependent increases in MWT sleep latency versus placebo and improved self‐reported alertness. NT1 showed a similarly robust, dose‐dependent response at lower doses, consistent with orexin‐deficient biology. These findings support OX2R agonism as a therapeutic approach for central disorders of hypersomnolence, including conditions with uncertain orexin dysfunction and informed ongoing phase 2 evaluation in IH and narcolepsy. Trial Registration: A study in healthy subjects to see the effects of the test medicine ALKS 2680 in single‐ and multi‐dose regimen; prospectively registered at ISRCTN on October 17, 2022 (identifier: ISRCTN98204977; URL: https://www.isrctn.com/ISRCTN98204977 ).
- 4 August 2026
- Published by Wiley in Journal of Sleep Research
- p. e70429
Open AccessTargeting Orexin 2 Receptors in Idiopathic Hypersomnia and Narcolepsy: A Randomised Phase 1b Proof‐Of‐Concept Study of Alixorexton
Idiopathic hypersomnia (IH) and narcolepsy type 2 (NT2) are central disorders of hypersomnolence characterised by excessive daytime sleepiness and substantial functional burden. Narcolepsy type 1 (NT1), defined by orexin deficiency, serves as an established biologic standard for evaluating therapies targeting the orexin system. Alixorexton (ALKS 2680) is a highly potent, oral, selective orexin 2 receptor (OX2R) agonist in clinical development for IH, NT2 and NT1. In this phase 1b, randomised, double‐blind, placebo‐controlled, four‐way crossover study (ISRCTN98204977), adults aged 18–65 years with IH ( n = 8), NT2 ( n = 9) or NT1 ( n = 10) received single oral doses of alixorexton (IH/NT2: 5, 12, 25 mg; NT1: 1, 3, 8 mg) and placebo across four treatment periods. The primary endpoint was safety and tolerability. Wakefulness was assessed by mean sleep latency on the Maintenance of Wakefulness Test (MWT) over 8 h post‐dose and subjective alertness by the Karolinska Sleepiness Scale (KSS). Alixorexton was generally well tolerated; all treatment‐emergent adverse events (TEAEs) were mild or moderate, with no serious TEAEs and no discontinuations due to TEAEs. In IH and NT2, alixorexton demonstrated statistically significant, clinically meaningful, dose‐dependent increases in MWT sleep latency versus placebo and improved self‐reported alertness. NT1 showed a similarly robust, dose‐dependent response at lower doses, consistent with orexin‐deficient biology. These findings support OX2R agonism as a therapeutic approach for central disorders of hypersomnolence, including conditions with uncertain orexin dysfunction and informed ongoing phase 2 evaluation in IH and narcolepsy. Trial Registration: A study in healthy subjects to see the effects of the test medicine ALKS 2680 in single‐ and multi‐dose regimen; prospectively registered at ISRCTN on October 17, 2022 (identifier: ISRCTN98204977; URL: https://www.isrctn.com/ISRCTN98204977 ).
- Open Access
- 27 February 2026
- Published by Elsevier in CHEST Pulmonary
- Vol. 4 (2) , 100245
The Role of Pharmacotherapy for Excessive Daytime Sleepiness in OSA
- 27 February 2026
- Published by Elsevier in CHEST Pulmonary
- Vol. 4 (2) , 100245
Open AccessThe Role of Pharmacotherapy for Excessive Daytime Sleepiness in OSA
- 16 February 2026
- Published by Wiley in Journal of Sleep Research
- Vol. 35 (4) , e70284
Cannabinol for Acute Treatment of Insomnia Disorder in a Randomized Placebo‐Controlled Crossover Trial
Insomnia disorder is harmful and requires novel treatments. Cannabinol, an oxidative by‐product of Δ9‐tetrahydrocannabinol, is claimed to be a hypnotic, but its effects on objective sleep and insomnia remain unknown. This randomized, double‐blind, placebo‐controlled, three‐arm, single‐night crossover trial evaluated the acute efficacy and safety of cannabinol for insomnia disorder. Twenty adults (aged 25–65) with physician‐diagnosed insomnia disorder (meeting DSM‐5 and ICSD‐3 criteria; Insomnia Severity Index ≥ 15) were enrolled at the Woolcock Institute of Medical Research (Sydney, Australia) between August 2022 and September 2023. Participants received a single 2 mL oral dose of 30 mg (1.5%) or 300 mg (15%) cannabinol, or matched placebo (2‐week washout). All participants (17 female and 3 males; mean ± SD age 42 ± 13 years) completed the protocol and were statistically analysed. The primary outcome was wake after sleep onset (WASO) minutes, measured by overnight polysomnography. Cannabinol did not significantly change WASO (300 mg: −6.3 min [95% CI: −18.2, +5.5], p = 0.29, dz = −0.22; 30 mg: −4.0 min [−15.9, +7.9], p = 0.50, dz = 0.11). However, 300 mg cannabinol increased non‐rapid eye movement‐2 sleep ( p = 0.03, dz = 0.54), subjective sleep quality ( p = 0.005, dz = 0.56); and reduced sleep onset latency ( p = 0.004, dz = −0.74) and electroencephalographic arousal indices ( p = 0.02, dz = −0.65). There were 247 mild‐to‐moderate adverse events across arms. Larger, longer trials are warranted. ClinicalTrials.gov Identifier: NCT05344170.
- 16 February 2026
- Published by Wiley in Journal of Sleep Research
- Vol. 35 (4) , e70284
Cannabinol for Acute Treatment of Insomnia Disorder in a Randomized Placebo‐Controlled Crossover Trial
Insomnia disorder is harmful and requires novel treatments. Cannabinol, an oxidative by‐product of Δ9‐tetrahydrocannabinol, is claimed to be a hypnotic, but its effects on objective sleep and insomnia remain unknown. This randomized, double‐blind, placebo‐controlled, three‐arm, single‐night crossover trial evaluated the acute efficacy and safety of cannabinol for insomnia disorder. Twenty adults (aged 25–65) with physician‐diagnosed insomnia disorder (meeting DSM‐5 and ICSD‐3 criteria; Insomnia Severity Index ≥ 15) were enrolled at the Woolcock Institute of Medical Research (Sydney, Australia) between August 2022 and September 2023. Participants received a single 2 mL oral dose of 30 mg (1.5%) or 300 mg (15%) cannabinol, or matched placebo (2‐week washout). All participants (17 female and 3 males; mean ± SD age 42 ± 13 years) completed the protocol and were statistically analysed. The primary outcome was wake after sleep onset (WASO) minutes, measured by overnight polysomnography. Cannabinol did not significantly change WASO (300 mg: −6.3 min [95% CI: −18.2, +5.5], p = 0.29, dz = −0.22; 30 mg: −4.0 min [−15.9, +7.9], p = 0.50, dz = 0.11). However, 300 mg cannabinol increased non‐rapid eye movement‐2 sleep ( p = 0.03, dz = 0.54), subjective sleep quality ( p = 0.005, dz = 0.56); and reduced sleep onset latency ( p = 0.004, dz = −0.74) and electroencephalographic arousal indices ( p = 0.02, dz = −0.65). There were 247 mild‐to‐moderate adverse events across arms. Larger, longer trials are warranted. ClinicalTrials.gov Identifier: NCT05344170.
- 5 December 2025
- Published by Springer Nature in Sleep and Breathing
- Vol. 30 (1) , 3
Early assessment in bulbar-onset amyotrophic lateral sclerosis detects similar rates of nocturnal desaturation and orthopnoea compared to non-bulbar-onset disease
Background Pulmonary function measures are commonly used to determine timing of non-invasive ventilation (NIV) initiation in amyotrophic lateral sclerosis (ALS). However, these tests may be difficult to perform and unreliable in those with bulbar disease. We evaluated the rates of orthopnoea and nocturnal desaturation detected using nocturnal pulse oximetry (NPO), two key criteria for NIV initiation, separately in people with bulbar-onset and non-bulbar-onset ALS. Methods We conducted a retrospective analysis of 93 individuals with ALS undergoing three consecutive nights of NPO screening. Demographics, diurnal respiratory function measures and NPO data were compared. Nocturnal desaturation was defined as > 2% of total sleep time with oxygen saturation < 90%. Results Twenty-nine people had bulbar-onset ALS and 64 had non-bulbar-onset ALS. The prevalence of orthopnoea and the proportion with nocturnal desaturation were similar between bulbar-onset and non-bulbar-onset groups (24% vs. 20% and 76% vs. 67%, respectively). People with bulbar-onset ALS were older and underwent initial oximetry earlier in their disease trajectory following ALS-symptom onset than those with non-bulbar-onset ALS (67 ± 10.5 vs. 61 ± 11.9 years old, p = 0.02 and 17.5 (11.00–24.75) vs. 31.0 (18.00–63.50) months, p = 0.005, respectively). Conclusion People with bulbar-onset ALS were assessed with NPO sooner, but nocturnal desaturation was detected at similar rates to those with non-bulbar-onset ALS. Absence of orthopnoea and preserved lung function were poor indicators of nocturnal desaturation in both groups. Given the difficulties performing respiratory function tests in people with bulbar disease, early and regular NPO assessment in bulbar-onset ALS is warranted, even without symptoms.
- 5 December 2025
- Published by Springer Nature in Sleep and Breathing
- Vol. 30 (1) , 3
Early assessment in bulbar-onset amyotrophic lateral sclerosis detects similar rates of nocturnal desaturation and orthopnoea compared to non-bulbar-onset disease
Background Pulmonary function measures are commonly used to determine timing of non-invasive ventilation (NIV) initiation in amyotrophic lateral sclerosis (ALS). However, these tests may be difficult to perform and unreliable in those with bulbar disease. We evaluated the rates of orthopnoea and nocturnal desaturation detected using nocturnal pulse oximetry (NPO), two key criteria for NIV initiation, separately in people with bulbar-onset and non-bulbar-onset ALS. Methods We conducted a retrospective analysis of 93 individuals with ALS undergoing three consecutive nights of NPO screening. Demographics, diurnal respiratory function measures and NPO data were compared. Nocturnal desaturation was defined as > 2% of total sleep time with oxygen saturation < 90%. Results Twenty-nine people had bulbar-onset ALS and 64 had non-bulbar-onset ALS. The prevalence of orthopnoea and the proportion with nocturnal desaturation were similar between bulbar-onset and non-bulbar-onset groups (24% vs. 20% and 76% vs. 67%, respectively). People with bulbar-onset ALS were older and underwent initial oximetry earlier in their disease trajectory following ALS-symptom onset than those with non-bulbar-onset ALS (67 ± 10.5 vs. 61 ± 11.9 years old, p = 0.02 and 17.5 (11.00–24.75) vs. 31.0 (18.00–63.50) months, p = 0.005, respectively). Conclusion People with bulbar-onset ALS were assessed with NPO sooner, but nocturnal desaturation was detected at similar rates to those with non-bulbar-onset ALS. Absence of orthopnoea and preserved lung function were poor indicators of nocturnal desaturation in both groups. Given the difficulties performing respiratory function tests in people with bulbar disease, early and regular NPO assessment in bulbar-onset ALS is warranted, even without symptoms.
- Open Access
- 1 November 2025
- Published by Springer Nature in Sleep and Breathing
- Vol. 29 (6) , 1-9
Prevalence and risk factors of obstructive sleep apnoea in people with sarcoidosis: a narrative review
Background: Emerging evidence suggests a link between sarcoidosis and obstructive sleep apnoea (OSA). Previous studies have reported a high prevalence of OSA in people with sarcoidosis; however, much of this evidence has been derived from retrospective analyses. Recently, prospective cohort studies have provided further insight into potential interactions between sarcoidosis and OSA. This narrative review aims to synthesise current evidence on the prevalence of OSA in people with sarcoidosis and identify associated risk factors. Methods: We conducted a search of Pubmed, Medline, the Cochrane Library and the Register of Controlled Trials and identified eight studies that evaluated the prevalence of OSA in people with sarcoidosis. Results: The prevalence of OSA in sarcoidosis patients ranged from 44% to 88%. Mild OSA was generally more common than moderate to severe OSA, with prevalence rates of 24% to 52% for mild cases and 5% to 51% for moderate to severe cases. Advancing age and elevated body mass index (BMI) were consistently associated with increased OSA risk. Corticosteroid therapy and sex showed mixed associations, while parenchymal lung involvement was not linked to increased OSA risk in any study. Conclusion: The prevalence of OSA in people with sarcoidosis is high. Conventional risk factors for OSA, including age and BMI, also apply in this group. Further prospective studies with larger, well-defined cohorts are warranted to clarify these associations and explore the potential bidirectional relationship between sarcoidosis and OSA. Studies should expand our knowledge on symptoms and hypoxic burden of subjects with sarcoidosis and OSA.
- 1 November 2025
- Published by Springer Nature in Sleep and Breathing
- Vol. 29 (6) , 1-9
Open AccessPrevalence and risk factors of obstructive sleep apnoea in people with sarcoidosis: a narrative review
Background: Emerging evidence suggests a link between sarcoidosis and obstructive sleep apnoea (OSA). Previous studies have reported a high prevalence of OSA in people with sarcoidosis; however, much of this evidence has been derived from retrospective analyses. Recently, prospective cohort studies have provided further insight into potential interactions between sarcoidosis and OSA. This narrative review aims to synthesise current evidence on the prevalence of OSA in people with sarcoidosis and identify associated risk factors. Methods: We conducted a search of Pubmed, Medline, the Cochrane Library and the Register of Controlled Trials and identified eight studies that evaluated the prevalence of OSA in people with sarcoidosis. Results: The prevalence of OSA in sarcoidosis patients ranged from 44% to 88%. Mild OSA was generally more common than moderate to severe OSA, with prevalence rates of 24% to 52% for mild cases and 5% to 51% for moderate to severe cases. Advancing age and elevated body mass index (BMI) were consistently associated with increased OSA risk. Corticosteroid therapy and sex showed mixed associations, while parenchymal lung involvement was not linked to increased OSA risk in any study. Conclusion: The prevalence of OSA in people with sarcoidosis is high. Conventional risk factors for OSA, including age and BMI, also apply in this group. Further prospective studies with larger, well-defined cohorts are warranted to clarify these associations and explore the potential bidirectional relationship between sarcoidosis and OSA. Studies should expand our knowledge on symptoms and hypoxic burden of subjects with sarcoidosis and OSA.
- Open Access
- 1 October 2025
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
- Vol. 22 (10) , 1467-1468
Unmasking Obesity Hypoventilation Syndrome Trajectories: Clustering Patient Journeys in Real-World Noninvasive Ventilation Use
- 1 October 2025
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
- Vol. 22 (10) , 1467-1468
Open AccessUnmasking Obesity Hypoventilation Syndrome Trajectories: Clustering Patient Journeys in Real-World Noninvasive Ventilation Use
- Open Access
- 12 September 2025
- Published by Elsevier in Sleep Medicine Reviews
- Vol. 84, 102169
Pharmacotherapy for obstructive sleep apnea: a critical review of randomized placebo-controlled trials
- 12 September 2025
- Published by Elsevier in Sleep Medicine Reviews
- Vol. 84, 102169
Open AccessPharmacotherapy for obstructive sleep apnea: a critical review of randomized placebo-controlled trials
- Open Access
- 13 August 2025
- Published by Wiley in Respirology
- Vol. 30 (10) , 920-922
Obstructive Sleep Apnoea Treatments—Where Are We Now?
- 13 August 2025
- Published by Wiley in Respirology
- Vol. 30 (10) , 920-922
Open AccessObstructive Sleep Apnoea Treatments—Where Are We Now?